pantethine (generic name)
treats Cystinosis, Athletic performance, Hyperlipidemia, and Ischemic heart disease
Table of Contents
Top Learning Centers(Recursos en Español)
SafetyDISCLAIMER: Many complementary techniques are practiced by healthcare professionals with formal training, in accordance with the standards of national organizations. However, this is not universally the case, and adverse effects are possible. Due to limited research, in some cases only limited safety information is available.
Avoid in individuals with a known allergy or hypersensitivity to pantethine or any component of the formulation.
Side Effects and Warnings
Pantethine is generally well tolerated. It may cause mild gastrointestinal side effects such as nausea, heartburn, or diarrhea. There is some evidence that pantethine can decrease platelet aggregation, which may increase the risk of bleeding.
Pregnancy and Breastfeeding
Pantethine is not recommended in pregnant or breastfeeding women due to a lack of available scientific evidence.
Interactions with Drugs
Theoretically, pantethine may increase the risk of bleeding when taken with drugs that increase the risk of bleeding. Some examples include aspirin, anticoagulants ("blood thinners") such as warfarin (Coumadin®) or heparin, anti-platelet drugs such as clopidogrel (Plavix®), and non-steroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen (Motrin®, Advil®) or naproxen (Naprosyn®, Aleve®).
Taking probucol or cysteamine may cause additive lipid-lowering effects. Caution is advised.
Interactions with Herbs and Dietary Supplements
In theory, pantethine may increase the risk of bleeding when taken with herbs and supplements that are believed to increase the risk of bleeding. Multiple cases of bleeding have been reported with the use of Ginkgo biloba, and fewer cases with garlic and saw palmetto. Numerous other agents may theoretically increase the risk of bleeding, although this has not been proven in most cases.
Use of pantethine with other lipid lowering agents, such as red yeast, may produce additive lipid-modulating effects. Caution is advised.
This information is based on a systematic review of scientific literature, and was peer-reviewed and edited by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com): Erica Seamon, PharmD (Nova Southeastern University); Kris Swinney, PharmD (Massachusetts College of Pharmacy); Isabell Syelsky, PharmD (Northeastern University); Brian Szczechowski, PharmD (Massachusetts College of Pharmacy); Shaina Tanguay-Colucci, BS (Natural Standard Research Collaboration); Chris Tonelli, MA (Emmanuel College); Catherine Ulbricht, PharmD (Massachusetts General Hospital); Wendy Weissner, BA (Natural Standard Research Collaboration); Jen Woods, BS (Northeastern University).
BibliographyDISCLAIMER: Natural Standard developed the above evidence-based information based on a thorough systematic review of the available scientific articles. For comprehensive information about alternative and complementary therapies on the professional level, go to www.naturalstandard.com. Selected references are listed below.
Angelico M, Pinto G, Ciaccheri C, et al. Improvement in serum lipid profile in hyperlipoproteinemic patients after treatment with pantethine: crossover, double blind trial versus placebo. Current Therapeutic Research 1983;33(June Sec 2):1091-1097.
Berni Canani M, Berni Canani R. Evaluation of the efficacy and tolerability of an association of cyproheptadine, carnitine and pantethine in the treatment of anorexia in children. Double blind clinical trial vs. cyproheptadine. Toxicologica et Therapeutica 1988;9(1):81-100.
Braverman ER. Nutrition for the heart. Part 2. Natural Pharmacy 1999;3:22-24.
Cattin L, Da Col PG, Fonda M, et al. Treatment of hypercholesterolemia with pantethine and fenofibrate; open randomized study on 43 subjects. Current Therapeutic Research 1985;38(Sep):386-395.
Da Col PG, Cattin L, Fonda M, et al. Pantethine in the treatment of hypercholesterolemia: a randomized double-blind trial versus tiadenol. Current Therapeutic Research 1984;38:719-727.
Harding JJ. Can drugs or micronutrients prevent cataract? Drugs Aging 2001;18(7):473-486.
Hiraoka T Clark JI. Inhibition of lens opacification during the early stages of cataract formation. Invest Ophthalmol.Vis.Sci. 1995;36(12):2550-2555.
Kelly GS. Nutritional and botanical interventions to assist with the adaptation to stress. Altern.Med.Rev. 1999;4(4):249-265.
McCarty MF. Inhibition of acetyl-CoA carboxylase by cystamine may mediate the hypotriglyceridemic activity of pantethine. Med.Hypotheses 2001;56(3):314-317.
Miller AL, Kelley GS. Homocysteine metabolism: nutritional modulation and impact on health and disease. Altern.Med.Rev. 1997;2(4):234-255.
Nomura H, Kimura Y, Okamoto O, et al. Effects of antihyperlipidemic drugs and diet plus exercise therapy in the treatment of patients with moderate hypercholesterolemia. Clin.Ther. 1996;18(3):477-482.
Osono Y, Hirose N, Nakajima K, et al. The effects of pantethine on fatty liver and fat distribution. J.Atheroscler.Thromb. 2000;7(1):55-58.
Pocecco, M. Treatment of infantile nephropathic cystinosis with cysteamine: 2. New England Journal of Medicine 1986;314(May 15):1320.
Slyshenkov VS, Rakowska M, Moiseenok AG, et al. Pantothenic acid and its derivatives protect Ehrlich ascites tumor cells against lipid peroxidation. Free Radic.Biol.Med. 1995;19(6):767-772.
Webster MJ. Physiological and performance responses to supplementation with thiamin and pantothenic acid derivatives. Eur.J Appl.Physiol Occup.Physiol 1998;77(6):486-491.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.